Case report and assessment of a novel chromosomal abnormality in AML affected person

A brand new analysis paper was revealed in Genes & Most cancers on June 28, 2023, entitled, “A novel t (5; 17) (q35; q21) related to t (8; 21) (q22; q22) in a affected person with acute myeloid leukemia: case report and assessment of literature.”

The t (8; 21) (q22; q22) with the ensuing RUNX1- RUNX1T1 rearrangement is likely one of the most typical cytogenetic abnormalities in acute myeloid leukemia (AML). It’s related to a good prognosis. The t (5; 17) (q35; q21) is an unusual translocation, fuses the gene for the nucleophosmin (NPM) to the retinoic acid receptor α(RARA) and was described primarily in acute promyelocytic leukemia (APL) variant.

In a brand new paper, researchers Kmira Zahra, Wided Cherif, Gereisha Ahmed, Haifa Regaieg, Ben Sayed Nesrine, Monia Zaier, Wided Mootamri, Yosra Ben Youssef, Nejia Brahem, Halima Sennana, and Abderrahim Khelif from Farhat Hached College Hospital-Sousse-Tunisia current the case of a 19-year-old male affected person who developed an AML with t (8; 21) (q22; q22) related to t (5; 17) (q35; 21).

Morphology and immunophenotype of the leukemic cells had been suitable with AML. The affected person acquired chemotherapy primarily based on cytarabine and anthracycline with out all-trans retinoic acid (ATRA) adopted by allogenic stem cell transplantation in first remission. To the very best of the researchers’ data, that is the primary report of an affiliation between a uncommon translocation t (5; 17) and t (8; 21) in AML.

“On this report, we’ll talk about the prognosis of this affiliation in addition to the therapy.”